

เอกสารอ้างอิง

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents (volume VIII). Lyon: IARC scientific publications; 1999.
2. Prechavittayakul, P (Editor). Tumor registry. Statistical report 2001. Songkhla: Songklanagarind Hospital; 2001.
3. Urba S. Esophageal cancer: preoperative or definitive chemoradiation. *Ann Oncol* 2004; 15 (Suppl 4); iv 93- 6.
4. Scheithauer W. Esophageal cancer: chemotherapy as palliative therapy. *Ann Oncol* 2004; 15 (Suppl 4); iv 97-100.
5. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies in cancer 2004. *Am J Clin Pathol* 2004 ; 122 : 598-609.
6. Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. *Semin Oncol* 2001; 28: 67-79.
7. Sunpaweravong P, Sunpaweravong S, Puttawibul P, et al. Epidermal growth factor receptor and cyclinD1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. *J Cancer Res Clin Oncol* 2004. Oct 19; (Epub ahead of print)
8. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD 1839) in Japanese patients with solid malignant tumors. *Annals of Oncology* 2003; 14: 922-30.
9. Goss G, Hirte H, Miller WH Jr, Lorimer IAJ, Stewart D, Batist G, et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND 122, a study of the investigational new drug program of the national cancer institute of Canada clinical trials group. *Investigational New Drugs* 2005; 23: 147-55.
10. Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. *Br J Cancer* 2005; 92: 1846-9.
11. Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. *Annals of Oncology* 2004; 15: 831-8.

12. Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. *J Clin Oncol* 2003; 21: 2094-100.
13. Jones HK, Stafford LE, Swaisland HC, Payne R. A sensitive assay for ZD 1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. *J Pharm Biomed Anal* 2002; 29: 221-8.
14. Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, et al. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. *Int J Pharm.* 2007 Aug 16; 341(1-2):134-42. Epub 2007 Apr 6.
15. Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. *Clin Pharmacokinet.* 2001; 40(4): 297-306.
16. Giaccone G, González-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. *Ann Oncol.* 2004 May; 15(5): 831-8.
17. Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. *Br J Cancer.* 2005 May 23; 92(10): 1846-9.
18. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. *J Clin Oncol.* 2002 Nov 1; 20 (21): 4292-302.
19. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. *Ann Oncol.* 2003 Jun; 14(6):922-30.
20. Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. *Br J Cancer.* 2004 Feb 9; 90(3): 566-72.



